StockData

Insmed vs Nasus Pharma

INSM and NSRX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How INSM and NSRX compare

Nasus Pharma keeps more of each dollar of sales as profit, with a net margin of −0.47% compared with −39.9% at Insmed.

Insmed scores higher on the StockData Score (8 against 6 for Nasus Pharma), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricINSMNSRX
Size and price
Market cap$26.6B–
Share price$121.16$2.87
Change, 1 year−37.7%−62.2%
Change, 5 years298%–
Beta (5Y)0.761.33
Employees1,664–
StockData Score
Total score8 (better)6
Valuation score00
Growth score3 (better)0
Performance score2 (better)1
Health score35 (better)
Dividend score00
Valuation
P/S17.5×–
P/B36.6×–
FCF yield−2.4%–
Fair value$60.58–
Margin of safety−100%–
Growth
Revenue growth (TTM)240%–
Revenue growth, 5Y average29.8%–
Profitability
Gross margin84.4%–
Operating margin−37.1%−0.40% (better)
Net margin−39.9%−0.47% (better)
FCF margin−41.3%−0.40% (better)
Return on equity−72.5% (better)−175%
Financial health
Debt / equity0.76 (better)0.00
Interest coverage−6.9×–
Current ratio2.868.77 (better)
Altman Z-score7.36–
Piotroski F-score44
Dividends and buybacks
Shareholder yield0.00%–
Ownership
Held by institutions102%23.9%
Held by insiders0.89%59.3%
Insider net buying, 12 months−$133M$61.8K (better)
Superinvestors holding1–
Short interest, % of float6.5%1.9%

Go deeper

Other comparisons

For information only, not investment advice. Check the source filings before relying on any figure.